STOCK TITAN

Vaxart (VXRT) Stock News

VXRT OTC

Vaxart, Inc. develops oral recombinant pill vaccines based on a proprietary delivery platform. The clinical-stage biotechnology company’s programs include vaccine candidates for coronavirus, norovirus and influenza, as well as a therapeutic human papillomavirus vaccine as its first immune-oncology indication. Its pill-based vaccines are designed for oral administration, storage and shipping without refrigeration, and avoidance of needle-stick risk.

Vaxart news centers on clinical data and scientific publications, business updates, financial results, financing arrangements, collaborations, intellectual property around adenovirus and TLR3 agonist oral vaccination technology, and governance changes as the company advances its oral vaccine pipeline.

Rhea-AI Summary

Vaxart (OTCQX: VXRT) reported third-quarter 2026 revenue of $10.620 million, alongside a wider net loss and updated vaccine development timelines. Revenue fell from $72.413 million a year earlier, while net loss widened to $17.689 million from $8.141 million. Loss per share was $0.07 versus $0.04.

Cash, cash equivalents and short-term investments totaled $65.5 million at September 30, 2026; the company expects its cash runway to extend into the second quarter of 2027. Vaxart expects Phase 2b COVID-19 efficacy and safety results by mid-year 2027, covering 400 sentinel safety participants and approximately 5,000 main-cohort participants. Cumulative BARDA contract cash payments reached $278.0 million. A new European norovirus vaccine patent extends protection through at least 2036. VXA-H5-02 showed complete protection against a fatal dose of the current dominant H5N1 strain in a preclinical study. Raquel Bono joined the board in October.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
-
Rhea-AI Summary

Vaxart (VXRT) will host a virtual stockholder fireside chat with senior management on November 6, 2026, at 4:30 p.m. ET. The event is part of its regular series answering frequently asked stockholder questions.

The company plans to report third-quarter 2026 financial results for the period ended September 30, 2026, after market close on November 5. Investors may submit questions beforehand by email or through the webcast portal. A replay will be available on Vaxart’s website after the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.07%
Tags
none
-
Rhea-AI Summary

Vaxart (OTCQB: VXRT) appointed retired U.S. Navy Vice Admiral Raquel C. Bono, M.D., to its Board of Directors. The appointment was made pursuant to a July 2026 cooperation agreement with a group of stockholders. Bono will chair the Stockholder Engagement Committee and serve on the Nominating and Governance Committee and the Clinical and Regulatory Affairs Committee.

A board-certified trauma surgeon, Bono previously directed the Defense Health Agency and currently serves as managing partner of NAVA Edge and on Humana’s board.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.04%
Tags
management
Rhea-AI Summary

Vaxart (VXRT) announced publication of a preclinical study showing 100% survival with its second-generation H5N1 vaccine candidate in challenged ferrets. The peer-reviewed results appeared in Frontiers in Immunology; topline results were previously reported in 2025.

All VXA-H5-02-immunized ferrets survived lethal H5N1 clade 2.3.4.4b challenge, while all unvaccinated controls died by Day 6 (p<0.001). Infectious viral shedding was approximately 2.3-log lower than controls by Day 3. Viable virus was below detection in nasal washes by Day 6–7, and 7 of 8 animals cleared viral RNA by Day 8/9.

The candidate elicited blood and nasal antibody responses, with cross-neutralizing activity against divergent H5 strains, including clade 2.3.2.1e. The clade-mismatched first-generation vaccine produced 37% survival. Researchers used intestinal liquid delivery to simulate tablet release because ferrets cannot use human tablets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.58%
Tags
none
-
Rhea-AI Summary

Vaxart (OTCQX: VXRT) announced that the European Patent Office has granted European Patent No. 3791859, effective August 26, 2026, covering its oral recombinant norovirus vaccine candidate.

The patent extends protection of Vaxart’s norovirus program and room‑temperature stable, needle‑free pill technology through at least 2036 across 13 major European jurisdictions, including Germany, France, Italy, Spain, and the United Kingdom, with validation planned in additional key territories.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
none
-
Rhea-AI Summary

Vaxart (OTCQX: VXRT) reported second quarter 2026 topline safety data from the 400-participant sentinel cohort of its Phase 2b COVID-19 oral pill vaccine trial, conducted against an approved mRNA comparator. No vaccine-related serious adverse events or sustained Grade 3+ adverse events were observed in either arm. The most common events for the pill were malaise/fatigue and headache, while the mRNA arm showed injection site pain/tenderness, malaise/fatigue, headache, and myalgia.

According to Vaxart, topline efficacy and safety data from the full Phase 2b study (about 5,400 participants) are expected in the first half of 2027. A BARDA contract modification increased authorized funding for the study to $344.8 million. Q2 2026 revenue was $27.2 million, primarily from government contracts and $2.9 million from a Dynavax agreement. R&D expense fell to $33.7 million, G&A rose to $6.6 million, and net loss narrowed to $13.5 million (or $0.06 per share). Cash, cash equivalents, and investments totaled $64.0 million at June 30, 2026, with an anticipated cash runway into the second quarter of 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.42%
Tags
Rhea-AI Summary

Vaxart (OTCQX: VXRT) will host a virtual stockholder fireside chat on Friday, August 7, 2026, at 4:30 p.m. ET / 1:30 p.m. PT as part of its regular FAQ-focused series for investors.

The company plans to report second quarter 2026 financial results for the period ended June 30, 2026, after market close on Thursday, August 6, 2026. The live webcast and replay will be available via www.vaxart.com, and investors can submit written questions in advance by email to IR@vaxart.com or through the webcast portal. Vaxart is a clinical-stage biotechnology company developing oral pill vaccines for coronavirus, norovirus, influenza and a therapeutic HPV program using its proprietary recombinant vaccine delivery platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.18%
Tags
none
-
Rhea-AI Summary

Vaxart (OTCQX: VXRT) announced that its management team will participate in the BTIG Biotechnology Conference 2026, held virtually on Tuesday, July 28, 2026, in a 1x1 meetings format.

The company develops oral recombinant pill vaccines targeting coronavirus, norovirus, influenza and a therapeutic HPV vaccine, using a proprietary non‑refrigerated delivery platform and has filed broad domestic and international patent applications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
none
-
Rhea-AI Summary

Vaxart (Nasdaq: VXRT) reported voting results from its July 16, 2026 Annual Meeting of Stockholders, held in a virtual-only format. Stockholders approved two proposals recommended by the Board: the election of six director nominees to serve until the 2027 Annual Meeting and the ratification of WithumSmith+Brown, PC as the independent registered public accounting firm.

Stockholders did not approve, on a non-binding advisory basis, the compensation of Vaxart’s named executive officers (“say-on-pay”) as disclosed in the proxy statement. According to Vaxart, final voting results will be filed with the SEC on a Form 8-K. The company also reiterated its focus on developing oral recombinant pill vaccines using its proprietary delivery platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.91%
Tags
none
Rhea-AI Summary

Vaxart (OTCQX: VXRT) reported topline 12‑month safety data from the 400‑participant sentinel safety cohort in its Phase 2b trial of an oral pill COVID‑19 vaccine versus an approved mRNA comparator targeting XBB.

No vaccine‑related SAEs or sustained Grade 3+ AEs occurred in either arm. Topline data from the full trial, including ~5,000 participants in the main KP.2 cohort, are anticipated in 2027. Vaxart’s Project NextGen award is valued at up to $344.8 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.81%
Tags
clinical trial covid-19

FAQ

What is the current stock price of Vaxart (VXRT)?

Vaxart (VXRT) last closed at $0.3617.

What is the market cap of Vaxart (VXRT)?

The market cap of Vaxart (VXRT) is approximately $88.2M.